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C-reactive protein (CRP), originally named for its capacity 
to precipitate the somatic C-polysaccharide of Pneumococcus 
pneumoniae, was the first acute phase protein to be described.32 
CRP belongs to the highly conserved pentraxin family of pro-
teins characterized by a cyclic pentameric structure with 
radial symmetry, and calcium-dependent ligand binding.16 
Based on the primary structure of the subunits, the pentraxins 
are divided into short and long pentraxins.26 CRP and serum 
amyloid P component are the prototype of the short pentraxin 
family, while pentraxin 3 is the prototypic long pentraxin.26 
The dog CRP molecule has a molecular mass of approxi-
mately 115 kDa and is composed of 5 subunits that are non-
covalently linked to each other.5 CRP is normally synthesized 
by hepatocytes at relatively low rates and retained in the 
endoplasmic reticulum.47 Serum CRP concentrations may 
increase more than 1,000-fold in response to the release of 
proinflammatory cytokines, most prominently interleukin-6 
(IL-6) and tumor necrosis factor-alpha (TNF-α), from mac-
rophages at the site of inflammatory lesions or infection.45 
Thus, CRP is well recognized as a sensitive systemic marker 
of the nonspecific acute phase response to most forms of 
tissue damage and inflammation in human beings, dogs, and 
pigs.6,9,32 In dogs, several studies have described increased 
levels of serum CRP in response to a variety of pathological 
conditions, including infectious diseases, traumata, surgery, 
systemic inflammatory response syndrome, or immune-
mediated diseases.7,8,13,15,18,30 Thus, serum CRP has been 
suggested as a major acute phase protein in dogs, and its 
measurement may contribute significantly to the detection, 
prognosis, and/or monitoring of the underlying disease.9
Recently, CRP was also detected in urine samples obtained 
from dogs with chronic renal disease.37 Chronic renal disease 
in dogs is progressive and typically ends in uremia and death.12 
Therefore, the identification of risk factors and improved 
diagnostic methods are needed because the detection of early 
stages of renal disease could help to slow down the progres-
sion of the disease.17,25 The determination of the glomerular 
filtration rate (GFR), usually measured as exogenous plasma 
creatinine clearance (P-Cl
Cr
) rate, is accepted as the best over-
all estimate of kidney function in dogs and can be used to 
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Abstract. The current study was undertaken to investigate the relation between serum C-reactive protein (CRP) concentrations 
and parameters of renal function in dogs with naturally occurring renal disease. Dogs were assigned to groups according 
to plasma creatinine concentration, urinary protein-to-creatinine ratio (UP/UC), and exogenous plasma creatinine clearance 
(P-Cl
Cr
) rates. Group A (healthy control dogs; n = 8): non-azotemic (plasma creatinine <125 µmol/l) and nonproteinuric (UP/
UC <0.2), with P-Cl
Cr
 rates >90 ml/min/m2; group B (n = 11): non-azotemic, nonproteinuric dogs with reduced P-Cl
Cr
 rates 
(50–89 ml/min/m2); group C (n = 7): azotemic, borderline proteinuric dogs (P-Cl
Cr
 rates: 22–67 ml/min/m2); and group D (n = 6): 
uremic, proteinuric dogs (not tested for P-Cl
Cr
). The serum CRP concentrations were measured via commercial enzyme-linked 
immunosorbent assay. The CRP concentrations in the clinically healthy dogs (group A) ranged from 2.09 mg/l to 8.60 mg/l 
(median: 3.21 mg/l). In comparison with dogs of group A, median CRP concentrations were significantly (P < 0.01) elevated 
in dogs of group B (17.6 mg/l, range: 17.0–19.2 mg/l), group C (24.8 mg/l, range: 18.0–32.5 mg/l), and group D (59.7 mg/l, 
range: 17.7–123 mg/l). Serum CRP was significantly related to P-Cl
Cr
 (r = –0.83; P < 0.001), plasma creatinine (r = 0.81; 
P < 0.001), UP/UC (r = 0.70; P < 0.001), and leukocytes (r = 0.49; P < 0.01). The significant relations between serum CRP 
concentrations and biochemical parameters of kidney function in plasma and urine suggest that a stimulation of the acute 
phase response is implicated in the pathogenesis of canine renal disease.
Key words: C-reactive protein; dogs; proteinuria; renal disease.
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evaluate onset and progression of renal disease in dogs.19,20,34,42 
Concentrations of plasma creatinine or plasma urea have been 
used as endogenous markers, but they provide only a crude 
estimate of GFR until 75% of kidney function has already 
been lost.17 Moreover, proteinuria is not only an indicator of 
renal diseases but is also associated with the rate of progres-
sion of renal disease, and inflammation may further contribute 
to the risk of developing end-stage renal failure.23,43 However, 
to the authors’ knowledge, no studies have investigated the 
relation of inflammatory biomarkers to renal function and/
or proteinuria in dogs. Therefore, the present study was con-
ducted to assess the CRP concentration in the serum of clini-
cally healthy dogs and in dogs with naturally occurring renal 
disease in order to find out if there is a relationship between 
CRP in serum and established markers of kidney function such 
as the P-Cl
Cr
 rate, plasma creatinine, and the urinary protein-
to-urinary creatinine (UP/UC) ratio.
Material and methods
Dogs and sampling
Blood and urine samples were obtained from 32 client- or 
student-owned dogs that were presented for blood donation 
or that were treated at the Small Animal Clinic of the Freie 
Universität Berlin, Germany. Eighteen male and 14 female 
dogs of various breeds (median age: 6.2 years; range: 1–14 
years) were included in the study. Blood and single voided 
urine samples (morning urines) were obtained from each 
dog after 12 hr of fasting. Dogs with underlying conditions 
(except renal diseases), such as infectious or inflammatory 
diseases, neoplastic diseases, endocrinopathies, and diseases 
of the lower urinary tract were excluded from the study. Blood 
samples were collected from a cephalic vein and placed in 
tubesa containing ethylenediamine tetra-acetic acid, lithium–
heparin, or a clotting activator. A complete blood cell countb 
was performed, and plasma and serum was prepared by cen-
trifuging blood samples (1,500 × g, 10 min at 4°C). The urine 
was centrifuged at 300 × g for 2 min for sediment analysis and 
for removal of cells and particulate matter. The supernatant, 
plasma, and serum were kept frozen at –80°C; the assays were 
performed within 4 months. The study protocol did not have 
to be approved by an animal welfare committee since sam-
ples were collected from dogs as part of their routine evalu-
ation at the hospital. Owner permission was obtained for use 
of the samples.
Measurement of renal function and  
group allocation
Biochemical testing for plasma creatinine was performed by 
the use of an automated analysis system.c Concentrations of 
urinary protein (UP) were assessed by a colorimetric assay.d 
Urinary creatinine (UC) was determined by the standard 
Jaffé reaction.c The UP/UC ratio was calculated in order to 
estimate the degree of proteinuria. The GFR was determined 
by use of a modified exogenous plasma clearance (P-Cl
Cr
) 
test in dogs that did not have clinical signs of uremia (i.e., 
inappetence, lethargy, and vomiting) or proteinuria together 
with azotemia.34 The exogenous P-Cl
Cr
 test was carried out 
with a single intravenous injection of 5% creatinine solutione 
at a dose of 2.4 g/m2 body surface area. Three blood samples 
were obtained during 4–9-hr intervals after creatinine injec-
tion; plasma creatinine was measured as previously described. 
The P-Cl
Cr
 was estimated as the amount of creatinine injected 
divided by the area under the curve calculated by the trape-
zoidal method by use of a noncompartmental model.19 The 
calculations were performed by use of a commercially avail-
able computer software program.38 An exogenous P-Cl
Cr
 rate 
≥90 ml/min/m2 was considered normal.20,34
For the group assignment of dogs after the P-Cl
Cr
 testing, 
reference values for plasma creatinine and UP/UC concen-
trations were based on the guidelines established by the 
International Renal Interest Society for dogs with chronic 
renal disease (Elliott J: 2006, Kidney disease—The IRIS con-
tribution. Proceedings of the 16th annual European College of 
Veterinary Internal Medicine–Companion Animals Congress, 
pp. 51–53, Amsterdam, The Netherlands). Azotemia was 
defined as plasma creatinine >125 µmol/l. Dogs were consid-
ered nonproteinuric if UP/UC was <0.2, borderline if UP/UC 
was 0.2–0.5, and proteinuric if UP/UC >0.5 mg/mg. On 
the basis of the results of plasma creatinine concentration, 
UP/UC, and exogenous P-Cl
Cr
 rate analysis, the dogs were 
assigned to 4 groups (Table 1). Dogs of group A (n = 8) were 
clinically healthy, non-azotemic, and nonproteinuric, and 
had P-Cl
Cr
 rates >90 ml/min/m2; group B (n = 11) consisted of 
non-azotemic and nonproteinuric dogs with reduced P-Cl
Cr
 
rates (51–76 ml/min/m2); group C (n = 7) included azotemic, 
borderline proteinuric dogs with P-Cl
Cr
 rates of 22–67 ml/min/m2; 
and group D (n = 6) included uremic and proteinuric dogs 
that were not tested for P-Cl
Cr
 because of their preexisting 
conditions.
Determination of C-reactive protein
C-reactive protein was determined in serum using a solid-phase 
sandwich enzyme-linked immunosorbent assayf (ELISA) 
according to the manufacturer’s instructions.24 The intra- and 
interassay coefficients of variation were 6.9% and 8.2% at 
CRP concentrations of 5.15 mg/l and 18.0 mg/l, respectively, 
according to the manufacturer’s information.
Statistical analysis
The results were expressed as medians and ranges. Statistical 
analysis was accomplished using a statistical computer 
application.g The Kruskal–Wallis test was used to test for 
significant differences in continuous variables between the 
groups. If there was a significant effect, the Mann–Whitney 
U-rank test was performed to describe differences in proportions 
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between case and control subjects. Spearman rank’s correla-
tion coefficients were used to compare serum CRP concentra-
tions and other analytes (P-Cl
Cr
, plasma creatinine, UP/UC, 
white blood cell count [WBC]). Values of P < 0.05 were 
considered significant.
Results
Azotemic dogs with borderline proteinuria (group C) and 
uremic dogs with overt proteinuria (group D) were older 
(P < 0.05) than dogs of groups A and B (Table 1). Age was 
significantly correlated with plasma creatinine (r = 0.55; 
P < 0.01), UP/UC (r = 0.37; P < 0.05), and CRP (r =0.46; 
P < 0.01), but it was not associated with the P-Cl
Cr
 rates 
(r = –0.35; P = 0.10).
In non-azotemic and nonproteinuric dogs with P-Cl
Cr
 rates 
>90 ml/min/m2 (group A), median concentrations of CRP 
were 3.21 mg/l (range: 2.09−8.60 mg/l). In comparison with 
dogs of group A, serum CRP concentrations were signifi-
cantly elevated in dogs of groups B–D (Fig. 1). Median 
CRP concentrations in non-azotemic and nonproteinuric 
dogs with reduced P-Cl
Cr
 rates (group B) were 17.6 mg/l 
(17.0−19.2 mg/l), in azotemic and borderline proteinuric dogs 
(group C) 24.8 mg/l (18.0−32.5 mg/l), and in uremic and pro-
teinuric dogs (group D) 59.7 mg/l (17.7−123 mg/l). Serum 
CRP was significantly correlated with P-Cl
Cr
 (r = −0.83; P < 
0.001), plasma creatinine (r = 0.81; P < 0.001), UP/UC (r = 
0.70; P < 0.001), and WBC (r = 0.49; P < 0.01; Table 2).
Discussion
It is well established that the concentration of serum CRP 
can increase significantly in many infectious and inflamma-
tory conditions and thus, might provide important diagnostic 
information to clinicians in veterinary medicine.7,8,13,15,18,30 
However, the contribution of chronic or recurring inflamma-
tion in the pathogenesis of renal disease in dogs is not well 
understood. Furthermore, it is not known whether serum 
CRP can be used as a diagnostic or prognostic marker of 
canine renal dysfunction. Therefore, the concentrations of 
CRP were determined in the serum of clinically healthy dogs 
with normal P-Cl
Cr
 (group A) and compared with CRP val-
ues obtained from clinically healthy dogs with reduced 
P-Cl
Cr
 (group B), azotemic and borderline proteinuric dogs 
with reduced P-Cl
Cr
 (group C), and uremic and proteinuric 
dogs (group D).
In the serum of healthy control dogs (group A), CRP con-
centrations were less than 10 mg/l, which is in accordance 
with the results reported by other investigators,21,24,39 who 
also used the solid-phase sandwich ELISAf for CRP determi-
nation. In several other studies that also used this assay, 
higher CRP levels were reported in clinically healthy dogs, 
which ranged from 9 mg/l to 31 mg/l,14 2.5–23.1 mg/l,7 or 
were 10.2 ± 2.9 mg/l (mean ± standard deviation).1 All results 
demonstrate a physiological variation of serum CRP in dogs 
under healthy conditions. Moreover, various assay methods 
are currently available for CRP measurement including 
Table 1. Median serum concentrations (range) of biochemical parameters of kidney function in 32 dogs.*
Parameter Group A (n = 8) Group B (n = 11) Group C (n = 7) Group D (n = 6)
Age (years) 3.5a (1–7) 5.0a (1–14) 6.0b (2–12) 10.0b (6–12)
Sex (male/female) 4/4 6/5 3/4 5/1
P-Cl
Cr
 (ml/min/m2) 110a (98–149) 63b (51–76) 40c (22–67) n/d
Creatinine (µmol/l) 81a (56–99) 101b (84–118) 167c (125–300) 900d (387–1176)
UP/UC (mg/mg) 0.03a (0.02–0.11) 0.03a (0.01–0.07) 0.27b (0.20–0.47) 4.63c (2.41–11.5)
WBC (×109/l) 8.09a (5.20–10.4) 7.31a (5.09–8.68) 9.40b (7.06–14.8) 13.4b (8.14–17.9)
*P-Cl
Cr
 = plasma creatinine clearance; UP/UC = urine protein-to-urine creatinine ratio; WBC = white blood cell count. a-dValues in the same row with 
different superscript letters differ significantly (P < 0.05). Group A: clinically healthy non-azotemic and nonproteinuric dogs; group B: non-azotemic and 
nonproteinuric dogs with reduced P-Cl
Cr
; group C azotemic and borderline proteinuric dogs; group D: uremic and proteinuric dogs.
Figure 1. Box plots of serum C-reactive protein (CRP) 
concentrations in clinically healthy non-azotemic and 
nonproteinuric dogs (group A), non-azotemic and nonproteinuric 
dogs with reduced P-Cl
Cr
 (group B), azotemic and borderline 
proteinuric dogs (group C), and uremic and proteinuric dogs 
(group D). The box represents the interquartile range (i.e., 
25–75% range), the horizontal bar represents the median value, 
and the T-bars represent the range of the data. Asterisk indicates 
significance (P < 0.01) when compared against group A.
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electroimmunoassay,5 single radial immunodiffusion,8 
ELISA,11,44 and turbidimetric immunoassay,10 so that the con-
centrations of serum CRP in dogs is dependent on the meth-
odology used. Therefore, further research is needed to assess 
reference values and especially upper limits for CRP in dogs 
under healthy conditions.
The important finding of the present study was that dogs 
with naturally occurring renal disease had significantly higher 
serum CRP concentrations compared to healthy control dogs. 
The median levels of CRP were highest in dogs with uremia 
and overt proteinuria, and were associated with a lower P-Cl
Cr
 
as well as increases in plasma creatinine, UP/UC, and WBC 
counts. These results suggest that an activation of the acute 
phase response and thus a low-grade inflammation might 
play a role in the pathogenesis of renal disease in dogs; but 
the detailed molecular mechanisms underlying this relation 
remain elusive. Hepatocytes produce circulating CRP in 
response to proinflammatory mediators, predominantly IL-6 
and TNF-α.32 But CRP may also be synthesized extrahepati-
cally as described for human peripheral blood mononuclear 
cells that express a transcript of the CRP gene.29 Studies with 
iodinated CRP in human beings have shown that approxi-
mately 70% of the protein is estimated intravascular,40 and 
that CRP is excreted in the urine of mice.28 Therefore, a 
retention of plasma CRP through a diminished glomerular 
filtration and reduced excretion of CRP can be proposed to 
explain higher CRP concentrations in renal disease.43 However, 
canine CRP is a high molecular weight plasma protein that is 
restricted from the glomerular filtration and is not detectable 
in the urine of healthy dogs.5,37 Therefore, the elevated CRP 
levels observed in dogs with renal disease cannot be explained 
by a retention of CRP due to impaired glomerular filtration. 
Only severe damage of the glomerular filtration membrane 
allows the filtration of high molecular weight proteins, and 
thus an excretion of CRP in the urine of dogs.37 Although 
CRP in urine was not measured in the current study, results 
showed that CRP was positively associated with UP/UC, and 
that despite the presence of severe proteinuria (UP/UC > 2.0), 
serum CRP was still elevated in dogs with uremia. A second 
explanation for higher CRP concentrations in renal disease 
might be the reduced clearance of inflammatory cytokines as 
reported in animal models of renal failure.2,33 Proinflammatory 
cytokines (e.g., IL-6 and TNF-α) play a central role in the 
activation of the acute phase response reflected in the pro-
duction of CRP and other acute phase reactants in the liver.32 
Even though concentrations of IL-6 were not determined in 
the present study, it was recently reported that the concentra-
tion of IL-6 is invariably elevated in dogs with end-stage 
renal disease.46 Therefore, the mechanism of a reduced renal 
cytokine clearance should be investigated in further studies. 
Third, renal disease is accompanied by increased oxidative 
stress resulting in an increased production of advanced oxi-
dation products that may stimulate CRP production by hepa-
tocytes, either directly or indirectly through the interaction 
with monocytes.3,27 Fourth, cell culture studies have shown 
that both mesangial cells and tubular epithelial cells synthe-
size pentraxins in response to inflammatory stimuli.4,31 CRP 
messenger RNA transcripts and CRP protein expression were 
reported in the kidneys, suggesting that the kidneys contribute 
to a local immune response.22
In the present study, the highest CRP values were observed 
in dogs with uremia and proteinuria (group D). Uremia is 
often accompanied by additional inflammatory conditions, 
such as uremic gastroenteritis and stomatitis, which may fur-
ther stimulate the acute phase response and with it serum 
CRP levels.1 The stimulation of the acute phase response 
might also explain the higher WBC counts compared to non-
azotemic dogs. Moreover, a recent study showed that the 
kidneys of dogs with end-stage renal disease contain a large 
number of infiltrated mononuclear inflammatory cells, which 
contribute to local inflammation and renal fibrosis in dogs 
with uremia.46 Another finding of the present study was that 
CRP is significantly positive related to UP/UC. In this regard, 
several experimental studies have shown that increased pro-
tein filtration and subsequent endocytosis by proximal tubular 
cells induce the synthesis of proinflammatory cytokines.36,41,48 
Proinflammatory cytokines may trigger the development of 
interstitial inflammation, which is thought to be responsible 
for progression of renal disease in proteinuric states,35 sug-
gesting that inflammation may be an important mechanism of 
proteinuria in dogs.
The present study has several limitations that should be 
addressed in future studies. First, a relationship between serum 
CRP and biochemical markers in the serum and urine of dogs 
with renal disease was observed. Therefore, it was not possible 
to determine whether serum CRP is a cause or consequence 
of renal dysfunction. Second, most dogs were only examined 
once in the current study. Therefore, the causality between 
serum levels of CRP and the progression of renal disease 
should be evaluated in a follow-up study, which should also 
include the histopathological investigation of renal biopsy or 
necropsy specimens in order to correlate the type of renal 
lesion with serum CRP in affected dogs.
In summary, the present study showed that an activated acute 
phase response is related to renal function as demonstrated by a 
Table 2. Correlation matrix of C-reactive protein (CRP) with 
other variables in 32 dogs.*




 Creatinine  0.81 <0.001
 UP/UC  0.70 <0.001
 WBC  0.49 <0.01
*P-Cl
Cr
 = plasma creatinine clearance; UP/UC = urine protein-to-urine 
creatinine ratio; WBC = white blood cell count. Spearman-rho correlation 
coefficients were calculated between serum CRP and clinical and 
biochemical variables, and significance was determined for a two-tailed 
distribution.
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significant correlation between serum CRP and reduced 
P-Cl
Cr
, increased serum creatinine, and elevated UP/UC. The 
findings deserve further investigations in dogs with renal 
disease to characterize the diagnostic and predictive value of 
CRP in this condition.
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